

4.0.3 DOC Cmte minutes

Parkinson's disease guideline committee meeting

Date: 18/04/16

Location: Manchester Central Library

Minutes: Final

Committee members present	
Paul Cooper (Chair)	Present for items 6-10
Janine Barnes (JB)	Present for all
Ivan Bennett (IB)	Present for all
Alistair Church (AC)	Present for all
Debbie Davies (DD)	Present for items 3-10
Julian Evans (JE)	Present for all
Robin Fackrell (RF)	Present for all
Richard Grunewald (RG)	Present for all
Graham Lennox (GL)	Present for all
Fiona Lindop (FL)	Present for all
Jane Little (JL)	Present for all
Lynne Osbourne (LO)	Present for all
Paul Shotbolt (PS)	Present for items 3-10
Matthew Sullivan (MS)	Present for all
Richard Walker (RW)	Present for all

In Attendance:		
Sue Spiers (SS)	Associate Director	Present for all
Steven Ward (SW)	Health Economist	Present for all
Joshua Pink (JP)	Technical Advisor	Present for all
Aimely Lee (AL)	Technical Analyst	Present for all
Daniel Davies (DaD)	Project Manager	Present for all

4.0.3 DOC Cmte minutes

Louise Picton (LP)	Analyst – Medicines Prescribing Centre	Present for all
Ben Doak (BD)	NICE Commissioning Manager	Present for items 5-10
Adam Storrow (AS)	Business Analyst	Present for items 1-6

Observers:

None

Committee member apologies:

None

Monday 18 April 2016

1. Welcome, introductions, minutes, DoI and matters arising

The Chair welcomed the Committee members and attendees to the tenth meeting on Parkinson's disease.

The Chair asked those present to declare any conflicts of interest relevant to the areas being discussed or potential new conflicts.

Name	Declaration	Classification	Chairs action
Richard Walker	Brittania sponsored attendance at Movement Disorders Conference in Berlin in June 2016	Specific, personal, financial (within NICE expense limit)	Declare and participate
Janine Barnes	Attendance at advisory board meeting arranged by Verto Health Consulting Ltd. Regarding a new MAOB inhibitor Safinamide. No honorarium received	Specific, personal, financial (within NICE expense limit)	Declare and participate
Janine Barnes	Attendance at	Specific, personal,	Declare and

4.0.3 DOC Cmte minutes

	advisory board meeting organised by Simon Kucher & Partners regarding a new clinical Apomorphine formulation. No honorarium received	financial (within NICE expense limit)	participate
Lynne Osborne	Attended pharmaceutical meeting (PINK) sponsored by Britannia Pharma.	Non-specific, personal, non-financial	Declare and participate
Lynne Osborne	Facilitating a South West Parkinson's Nurse Specialist meeting sponsored by a selection of pharma companies.	Non-specific, personal, non-financial	Declare and participate
Robin Frackell	BIAL sponsored attendance at Movement Disorders Conference in Berlin in June 2016	Specific, personal, financial (within in NICE expense limit)	Declare and participate

It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The committee reviewed the minutes of the previous meeting and agreed they were an accurate record of the discussions.

PC confirmed that the main objectives for the day were to consider clinical and economic data for review question 14, and to agree draft recommendations.

2.Resource impact process

AS provided an overview of NICE's policy with regard to consideration of resource impact when making guideline recommendations and how this may affect the recommendations within the Parkinson's Disease guideline.

4.0.3 DOC Cmte minutes

3. Editorial meeting dates
SS provided the committee with information regarding provisional editorial meeting dates for developing supporting publications for the guideline. She asked for any volunteers from the committee to attend these dates and encouraged any interested individuals to contact DaD to express an interest.
4. Discussion of criteria for review question 14 study inclusion
The committee discussed and agreed the criteria for study inclusion when examining evidence for review question 14.
5 and 6. Clinical data for review question 14
JP and AL presented the clinical evidence for review question 14. The evidence was discussed by the committee. The committee considered and discussed the evidence but deferred making any recommendations until they had been presented with the health economic evidence supporting these review questions.
7. Update on NHS England duodopa policy
BD provided a short update on the NHS England duodopa policy
8. Health economic model for question 14
SW presented data relating to published health economic evaluations relating to review question 14. The committee discussed the merits of these analyses and their ability to inform their decision making.
9. Agreement of draft recommendations for review question 14
The committee discussed the evidence presented earlier in the day and made draft recommendations for review question 14 based on the evidence presented and their clinical experience and expertise.
8. AOB
The chair thanked the group for their attendance and contributions, and noted that the next meeting would be held on 09 June 2016 in London.